Indications & Use

Iodine[¹²⁵I] Brachytherapy Source with apparent activities from 11.1MBq to 37.0MBq are indicated for permanent interstitial implantation of selected localized tumors which are of low to moderate radiosensitivity. They may be used either as primary treatment such as for prostate cancer or unresectable tumors or for treatment of residual disease after excision of the primary tumor. The source in this apparent activity range may be used to treat superficial, intraabdominal, and intrathoracic tumors. Tumors of the head, neck, lung, pancreas, and prostate of early stages are commonly treated. In addition, this products are indicated to treat residual tumors concurrent with or at the completion of other treatment modalities, such as external beam radiation therapy.

Radionuclide Half-life

59.43 days

Apparent Activities

11.1MBq-37.0MBq (0.3mCi-1.0mCi)

Effective Period

60 days